Tyme Technologies, Inc. is a biopharmaceutical firm dedicated to developing cancer metabolism-based therapies (CMBTs) within the United States. Its flagship therapeutic candidate, SM-88, is currently undergoing Phase II/III clinical evaluation across 15 distinct cancer types, including but not limited to pancreatic, prostate, breast, lung, glioma, ovarian, sarcoma, and colon. The company's pipeline also includes TYME-19, an orally administered synthetic bile acid derivative in preclinical stages for combating SARS-CoV-2 infections, and TYME-18, another preclinical CMBT compound designed to treat tumors that are inoperable. Tyme Technologies maintains research partnerships, notably with the Mayo Clinic for comprehensive analysis of SM-88's impact on pancreatic cancer cell gene expression, epigenetics, and metabolic changes, and with a research investigator at Georgetown University to study SM-88's effects in breast cancer. Founded in 2011 as Global Group Enterprises Corp. and headquartered in Bedminster, New Jersey, Tyme Technologies, Inc. has been operating as a subsidiary of Syros Pharmaceuticals, Inc. since September 16, 2022.


Net sales
Gross margin
Net income